Navigation Links
Taking a cue from nature
Date:10/30/2013

It's not unusual for scientists to take their cues from nature. In fact, Jeff Rimer is building much of his career on such cues.

Rimer, an assistant professor of chemical and biomolecular engineering with the University of Houston Cullen College of Engineering, is an expert in the field of crystallization. The processes behind crystal growth and formation impact everything from drug development to chemical synthesis to medical diseases such as kidney stones and malaria.

One of the primary efforts of Rimer's lab involves a class of crystals known as zeolites. These are widely used by the chemical and petrochemical sector as catalysts, which initiate or speed up chemical reactions. A material will diffuse through pores in a zeolite crystal, react with specific sites in the crystal interior, and then exit, transformed into a more useful chemical. Rimer is attempting to control how zeolites grow in order to make them more efficient catalysts for commercial reactions.

"The original work I performed with modified zeolite synthesis was inspired by processes in natural mineral formation," said Rimer. "Sponges and diatoms form amorphous silica exoskeletons. They possess elaborate hierarchical structures that are created through specific interactions with proteins."

Rimer, then, has identified and developed a number of molecules that, in a similar manner, alter the growth and shape of zeolites in order to optimize their catalytic properties. He has won multiple grants supporting this work (including a National Science Foundation CAREER Award), has published extensively on his findings and is even pursing a patent for a method to rationally design new zeolites.

Rimer's latest grant in this area comes from the United States-Israel Binational Science Foundation, an independent body formed though an agreement between the two countries. He and his collaborator, Galia Maayan from the Technion - Israel Institute of Technology (often called Israel's MIT), received a two-year, $150,000 award to develop a class of molecules called peptoids that will be designed to alter zeolite growth.

This latest grant covers zeolites that, when unmodified, are shaped like cylinders, with their pores running the length of the cylinder. Molecules that enter these pores must travel much farther than needed during the course of the reaction. As a result, the catalysts are more susceptible to the formation of coke, a carbon-rich deposit that blocks the pores and deactivates the catalyst.

Like all crystals, these zeolites grow when new molecules of the crystal material attach to specific locations (known as growth sites) on the zeolite surface. Rimer and Maayan are developing peptoids that bind to the zeolite surfaces at these sites. A segment of the peptoid will then physically block the growth sites, thus frustrating the attachment of additional molecules to the crystal.

By blocking these sites, he aims to change the shape of these zeolites from cylinders to flat platelets. This will significantly improve the lifetime of catalysts by reducing coke formation in various reactions. As a result companies should be able to carry out these processes more efficiently and for less money than before.

Just as importantly, using modified zeolites would require little to no changes in the manufacturing processes used by companies in the chemicals sector, said Rimer.

"This is something that could be integrated into an existing process very easily, without requiring equipment upgrades or dramatic changes in operating conditions," Rimer explained. "So from an economic perspective, this could be very attractive for industry."


'/>"/>

Contact: Jeannie Kever
jekever@uh.edu
713-743-0778
University of Houston
Source:Eurekalert

Related biology news :

1. An invasive Asian fly is taking over European fruit
2. Young researcher taking fight against global killer to the next level in Vietnam
3. Taking Americas rarest snake back to the woods
4. Taking a hit or 2
5. Taking the pulse of volcanoes using satellite images
6. Taking the gamble out of DNA sequencing
7. Study finds taking probiotics has benefits for patients in hospitals
8. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
9. Epigenetic signatures direct the repair potential of reprogrammed cells
10. Nature: Video reveals wave character of particles
11. 2012 ACMG Foundation/Signature Genomic Laboratories Travel Award winner announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
(Date:12/16/2016)... NEW YORK , Dec. 16, 2016 The global ... reach USD 12.14 billion by 2021 from USD 5.31 billion in ... ... market is mainly driven by technological advancements in medical devices, launch ... devices, rising preference for wireless connectivity among healthcare providers, and increasing ...
(Date:12/15/2016)... ... Markets has announced the addition of the "Global Military Biometrics Market ... the global military biometrics market to grow at a CAGR of 7.5% ... based on an in-depth market analysis with inputs from industry experts. The ... years. The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... ... January 12, 2017 , ... ... INTERFUSE® IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful ... laterally expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered ...
(Date:1/12/2017)... , January 12, 2017 ... the world,s biggest facility for producing mycorrhizae. The Centre ... nutrient tapping potential of mycorrhizae and developed a technology ... ... http://mma.prnewswire.com/media/456932/PRNE_TERI_Logo.jpg) The TERI facility has ...
(Date:1/11/2017)... ... 11, 2017 , ... Phase 1 clinical trial data published ... investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The 50 women ... these heavily pretreated patients saw clinical benefit from the drug, with at least ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... year and costing healthcare systems more than $23.7 billion, healthcare systems are ... , Among the most common sepsis-causing pathogens are bacteria and the yeast ...
Breaking Biology Technology: